Selective protein degradation plays an important regulatory role in a variety of organismal processes, including the removal of potentially toxic proteins and misfolded proteins to regulate cell cycle progression and gene expression (Glickman and Ciechanover, 2002), and proteasome inhibitors have been shown to have antitumor properties and have been used in clinical settings (Manasanch and Orlowski, 2017), and results have shown that CRC cells can evade proteotoxic stress responses by reducing PSMD5 stimulation of 26S proteasome assembly (Levin et al., 2018). Here, PSMD5 is linked to colorectal carcinoma.